Genotipificación del Virus de Papiloma Humano en mujeres de la comuna norte de Bucaramanga

Abstract

Introduction: Persistent infection with high-risk Human Papilloma Virus is a necessary cause for the appearance of cervical cancer. Objective: Molecularly characterize circulating genotypes of Human Papilloma Virus in population of the north of Bucaramanga. Methods: cross-sectional study in women aged from 35 to 65 years with risk ≥3 points for develop cervical cancer determined by a standardized survey. In a cervico-vaginal self-sampling probe a molecular test was performed by HPV Direct Flow CHIP technology. Results: 810 women were interviewed, of these 435 (53.7%) performed self-sampling due to the risk calculated. The median age was 47.3 years (RIQ 41-53 years). Almost the entire population resides in poor conditions (stratum1 and 2) (98.8%) and most of them are from the Colombian subsidized social security system (87.2%). The prevalence was 10.6% (CI 95%: 7.8 - 13.8), for high risk genotypes it was 3.9% (CI 95%: 2.3 - 6.2), low risk of 3.5% (CI 95%: 1.4 - 5.6) and for indeterminate genotype of 1.9%. HPV-59 was the most common high-risk genotype and HPV-62/81 was a low-risk genotype. There was coinfection with high risk/low risk genotypes in five women and coinfection with two low risk genotypes in a woman. Conclusion: The prevalence of infection by Human Papilloma Virus in women living in vulnerable areas of Bucaramanga is lower than that reported in Bogotá and Cali (14.9% and 13%, respectively). No predominance of any particular high-risk genotype was found. Abstract Objective: To address neurological symptoms from the perspective of palliative care through the review of available scientific literature taking into account the theoretical components of the Revised Symptom Management Model of Marylin J. Dodd. Methodology: Following the steps proposed by the PRISMA statement, a systematic review was made of the publications made between 2002 and 2017, of related articles that addressed neurological symptoms from the perspective of palliative care applying any of the components of the Revised Symptom Management Model of